My ePortfolio Register   

Clinical potential of trastuzumab biosimilar CTP6

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.06.17
Views: 699
Rating:

Prof Francisco Esteva - NYU Langone Medical Center, New York, USA

Prof Esteva speaks with ecancer at ASCO 2017 about his work, recently published in The Lancet Oncology, about the possible utility of trastuzumab biosimilars.

He describes the combination of CTP6 with chemotherapy as having a similar safety profile, efficacy and pathologic response as trastuzumab, and considers the staging of neoadjuvant therapy for recently diagnosed breast cancer.

 

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence